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ORIGINAL RESEARCH ARTICLE
High-resolution proteomic and lipidomic analysis of
exosomes and microvesicles from different cell sources
Reka A. Haraszti1,2, Marie-Cecile Didiot1,2, Ellen Sapp3, John Leszyk4,
Scott A. Shaffer4, Hannah E. Rockwell5, Fei Gao5, Niven R. Narain5,
Marian DiFiglia3, Michael A. Kiebish5, Neil Aronin1,6* and
Anastasia Khvorova1,2*
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA; 2Program in
Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA; 3MassGeneral
Institute for Neurodegenerative Disease, Charlestown, MA, USA; 4Mass Spectrometry Core, University of
Massachusetts Medical School, Worcester, MA, USA; 5Berg LLC, Framingham, MA, USA; 6Department of
Medicine, University of Massachusetts Medical School, Worcester, MA, USA
Extracellular vesicles (EVs), including exosomes and microvesicles (MVs), are explored for use in diagnostics,
therapeutics and drug delivery. However, little is known about the relationship of protein and lipid composition
of EVs and their source cells. Here, we report high-resolution lipidomic and proteomic analyses of exosomes and
MVs derived by differential ultracentrifugation from 3 different cell types: U87 glioblastoma cells, Huh7
hepatocellular carcinoma cells and human bone marrow-derived mesenchymal stem cells (MSCs). We identified
3,532 proteins and 1,961 lipid species in the screen. Exosomes differed from MVs in several different areas: (a)
The protein patterns of exosomes were more likely different from their cells of origin than were the protein
patterns of MVs; (b) The proteomes of U87 and Huh7 exosomes were similar to each other but different from the
proteomes of MSC exosomes, whereas the lipidomes of Huh7 and MSC exosomes were similar to each other but
different from the lipidomes of U87 exosomes; (c) exosomes exhibited proteins of extracellular matrix, heparin-
binding, receptors, immune response and cell adhesion functions, whereas MVs were enriched in endoplasmic
reticulum, proteasome and mitochondrial proteins. Exosomes and MVs also differed in their types of lipid
contents. Enrichment in glycolipids and free fatty acids characterized exosomes, whereas enrichment in
ceramides and sphingomyelins characterized MVs. Furthermore, Huh7 and MSC exosomes were specifically
enriched in cardiolipins; U87 exosomes were enriched in sphingomyelins. This study comprehensively analyses
the protein and lipid composition of exosomes, MVs and source cells in 3 different cell types.
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E
xtracellular vesicles (EVs) occur in most bodily
fluids and cell culture supernatants. With the
advent of parallel sequencing technologies, the
RNA content of EVs is being heavily investigated as a
new type of diagnostic biomarker (1). The RNA contents
of EVs from a variety of bodily fluids, including urine,
saliva, blood and cerebrospinal fluid, have been explored
as biomarkers for indications throughout the body (28).
EVs as tumour biomarkers are especially valuable, since
bodily fluid EVs provide an alternative to repeated
biopsies for continuous monitoring and an option for
tumours inaccessible to biopsies (i.e. brain tumours). EVs
are also being explored as natural carriers of therapeutic
RNAs (9,10). EVs for therapeutic applications are typi-
cally derived from mesenchymal stem cells (MSCs), a cell
type well characterized for cell-based therapies (10,11).

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Two EV subgroups in particular, exosomes and micro-
vesicles (MVs), have the ability to carry biomarkers or
therapeutic RNA. Exosomes are small vesicles (tradition-
ally considered 50150 nm) that originate from endocytic
compartments within the cell. During endosome matura-
tion, intraluminal vesicles are formed by endosomal
membrane budding inside multivesicular bodies, and
intraluminal vesicles become exosomes upon the exocy-
tosis of multivesicular bodies (12). Compared with exo-
somes, MVs are larger vesicles (traditionally considered
2001,000 nm) and are formed by budding directly from
the plasma membrane (13). Available purification methods
include separation based on size [differential ultracentri-
fugation (14) and ultrafiltration (15)], density [OptiPrepTM
(16) and sucrose (17)], floatation velocity (18), immuno-
affinity (19) and polyethylene glycol (PEG)-based precipi-
tation (15). These strategies enrich EVs within certain size
ranges but are not able to fully separate EV subgroups,
resulting in mixed EV populations in the isolates (20). The
purification strategy defines the nature of EV subgroup
mixture in the isolate, which in turn will determine its
biological function and biochemical properties. Further-
more, EV purification strategies can co-isolate non-
vesicular extracellular proteins and lipoprotein particles
with EVs.
The protein and lipid compositions of EVs from
various sources have been studied via biochemical assays
and mass spectrometry (2134) and provide a robust basis
for protein biomarker identification in EVs for research
quality control purposes. Exosomal isolates commonly
contain membrane proteins, specifically tetraspanins, as
well as various amounts of extracellular matrix proteins;
they are devoid of nuclear proteins (16). Microvesicular
isolates may contain proteins of mitochondrial or en-
doplasmic reticulum origin (16). A detailed understanding
of the biochemical (protein and lipid) composition of
EV subgroups and the extent to which EV composition
reflects source cell composition is necessary for further
development into diagnostics and therapeutics. To ad-
dress this question, we performed a comparative analysis
of the protein and lipid composition of 2 EV subgroups
and their source cells. We chose a glioblastoma (U87)
and a hepatocellular carcinoma (Huh7) cell line, since
the EVs of these tumour types are in the focus of interest
for diagnostic biomarker development (6,35). We further
chose bone marrow-derived MSCs, since this cell type
is frequently used for therapeutic vesicle production
(10). For EV purification, we sought a strategy that would
not introduce bias into the composition of EV isolates
(unlike immunoaffinity-based purification), would not co-
enrich non-vesicular extracellular proteins (unlike PEG
precipitation) (15) and would provide sufficient yield
for mass spectrometric measurement. Differential ultra-
centrifugation is considered the gold standard of EV
purification and met the above requirements.
Materials and methods
Preparation of EVs
U87 glioblastoma and Huh7 hepatocellular carcinoma
cells were cultured in Dulbecco’s modified eagle medium
(DMEM) and human bone marrow-derived MSCs
(Lonza) in MSC basal medium (Lonza). Before EV
purifications, cells were incubated with EV-depleted me-
dium for 34 days (medium was centrifuged overnight at
100,000g to pellet out vesicles). A volume of 360-mL
conditioned medium was collected from the culture of
approximately 80% confluency and EVs prepared by
differential ultracentrifugation (14). Briefly, cell debris
was pelleted at 500g. Then, MVs were pelleted at 10,000g
(30 min), supernatant filtered through a 0.2-mm membrane
(Nalgene† aPES, Thermo Fisher Scientific, Waltham,
MA) and exosomes pelleted at 100,000g (90 min). Con-
centrations and size distribution were measured by Nano-
particle Tracking Analysis (NanoSight NS300, Malvern).
Briefly, samples were diluted in phosphate buffered saline
(PBS) 1:1001:1,000, manually injected into the instru-
ment and videos acquired at ambient temperature at
camera level 9 for 1 min per sample, and videos processed
at threshold level 10. We purified EVs from all 3 source cell
types on 6 different days, and used 3 isolates for proteomics
and the other 3 isolates for lipidomic analysis. All 6 isolates
underwent Nanoparticle Tracking Analysis before being
stored at808C until further processing for proteomics or
lipidomics.
Electron microscopy
The samples and grids for electron microscopy were
prepared at room temperature. An equal volume of 4%
paraformaldehyde was added to the exosome sample and
incubated for 2 h. Three-microlitre aliquots of exosomes
were dropped onto grids and incubated in 2% paraformal-
dehyde for 20 min. The grids were transferred to awax strip
and washed with 100 ml PBS. The grids were incubated in
50 mM glycine/PBS for 5 min and blocked in 5% bovine
serum albumin (BSA)/(PBS) for 10 min and washed with
3PBS followed by incubation in 1% glutaraldehyde for 5
min. Following 8 washes of 2 min with H2O, the grids were
incubated for 5 min in uranyl oxalate and in 1% methyl
cellulose: 4% uranyl acetate (9:1) for 10 min on ice. Excess
liquid was removed with a filter paper, and the grids were
air-dried for 510 min. Exosomes were examined in a
JEOL 1100 transmission electron microscope (JEOL,
Peabody, MA) at 60 kV, and images were obtained with
an AMT digital camera (Advanced Microscopy Techni-
ques, Woburn, MA).
Western blotting
EV pellets or cell pellets were suspended in radioimmuno-
precipitation assay (RIPA) buffer (Pierce† 899000,
Thermo Fisher Scientific) containing phenylmenthylsulfonyl
fluoride (PMSF) (36978, Thermo Fisher Scientific) and
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protease inhibitor cocktail (cOmplete Mini, 11836153001,
Roche), and samples were sonicated for 15 min. Insoluble
material was pelleted by centrifugation for 15 min at 13,000
rpm at 48C. Supernatants were transferred to a new tube,
and protein concentrations measured by Bradford assay.
Proteins (50 mg) were loaded and simultaneously analysed
on NuPAGE 412% Bis-Tris gels (Invitrogen). After transfer
to polyvinylidene fluoride (PVDF) (BioRad) membranes,
antibody incubation and development was performed using
Odyssey† system (Li-Cor) according to manufacturer’s
instructions. Primary antibodies used were calnexin (Cell
Signaling, C5C9), CD9 (Santa Cruz, C4), CD63 (BD
Biosciences, H5C6), CD81 (Santa Cruz, B11) and Tsg101
(Abcam, 4A10).
Proteomics
Protein extraction followed the same protocol as for
Western blotting. Total protein (100 mg) was applied to
an SDSPAGE. Once the entire protein sample entered
the stacking gel, electrophoresis was stopped and the
portion of gel containing proteins was excised and stained
with Coomassie brilliant blue. The fixed gel fragments
were processed by University of Massachusetts Medical
School Mass Spectrometry Core. Gel slices were cut into
11 mm pieces, placed in 1.5-ml microcentrifuge tubes
containing 1-ml water and incubated for 30 min. The
water was replaced with 200 ml of 250 mM ammonium
bicarbonate and 25 ml of 45 mM dithiothreitol (DTT),
and the samples were incubated for 30 min at 508C.
Samples were then cooled to room temperature, and
alkylation was performed by adding 25 ml of 100 mM
iodoacetamide and incubating for 30 min. The gel slices
were washed twice in water, and then incubated in 1 ml of
a 50:50 solution of 50 mM ammonium bicarbonate/
acetonitrile for 1 h at room temperature. The solution
was replaced with 200 ml acetonitrile and incubated until
the gel slices turned opaque white. The acetonitrile was
removed, and gel slices were further dried in a Speed Vac.
Gel slices were rehydrated in a 100-ml solution of 50 mM
ammonium bicarbonate containing 0.01% ProteaseMAX
Surfactant (Promega) and 2 ng/ml trypsin (Sigma). Addi-
tional bicarbonate buffer was added to ensure complete
submersion of the gel slices. Samples were incubated for
21 h at 378C. Supernatants were transferred to a fresh 1.5-
ml tube. Gel slices were further dehydrated with 200 ml of
an 80:20 solution of acetonitrile/1% formic acid. The
extract was combined with the supernatants of each
sample. The combined supernatants containing digested
proteins were then dried in a Speed Vac, and pellets were
redissolved with 25 ml of 5% acetonitrile in 0.1%
trifluoroacetic acid. A 3.5-ml aliquot was directly injected
onto a custom-packed 2 cm100 mm C18 Magic 5 mm
particle trap column. Peptides were then eluted and
sprayed from a custom-packed emitter (75 mm25 cm
C18 Magic 3-mm particle) with a linear gradient from 95%
solvent A (0.1% formic acid in water) to 35% solvent B
(0.1% formic acid in acetonitrile) at a flow rate of 300 nl
per minute for 120 min on a Waters Nano Acquity UPLC
system. Data-dependent acquisitions were performed on a
Q Exactive mass spectrometer (Thermo Scientific) ac-
cording to an experiment where full MS scans from 300 to
1,750 m/z were acquired at a resolution of 70,000 followed
by 10 MS/MS scans acquired under higher-energy colli-
sional dissociation (HCD) fragmentation at a resolution
of 17,500 and an isolation width of 1.6 Da. Raw data files
were processed with Proteome Discoverer (version 1.4)
before using Mascot Server (version 2.5) to search against
the Uniprot_Human protein database. Applied search
parameters were fully tryptic with 2 missed cleavages,
parent mass tolerances of 10 ppm and fragment mass
tolerances of 0.05 Da, and allowed for fixed modification
of carbamidomethyl cysteine and variable acetyl-group
modifications at the N-termini, for example, pyrogluta-
mate for N-term glutamine and oxidation of methionine.
Search results were loaded into the Scaffold Viewer
(Proteome Software, Portland, OR) to validate and
quantify peptides.
Lipidomics
MV and exosome samples were pelleted at 10,000 and
100,000g, respectively. Pellets were frozen at 808C and
transferred to Berg LLC (Framingham, MA) on dry ice
for lipid composition analysis.
Aliquots of each sample were combined with a cocktail
of deuterium-labelled and odd chain fatty acid standards.
Standards were chosen that represent each lipid class and
were at designated concentrations expected to provide
the most accurate quantitation of each lipid species. Lipids
were extracted with 4 ml of a 1:1 (v/v) solution
of chloroform/methanol as previously described (36),
using an automated custom sequence routine on a Star
Hamilton Robotics system (Hamilton, Reno, NV). Lipid
extracts were dried under nitrogen, and pellets were
dissolved in 300 ml of a 1:1 (v/v) solution of chloroform/
methanol per mg of protein. Samples were flushed with
nitrogen and stored at 208C. For MS analysis, samples
were diluted 50-fold in 3:3:3:1 (v/v/v/v) isopropanol/
methanol/acetonitrile/water containing 2 mM ammonium
acetate to enhance ionization efficiency in positive and
negative modes. Electrospray ionization MS was per-
formed on a SCIEX TripleTOF† 5600 (SCIEX) coupled
to a customized direct injection loop system on an Ekspert
microLC200 system. Fifty microlitres of sample was
injected at a flow rate of 6 ml/min. Lipids were analysed
using a customized data independent analysis strategy on
the TripleTOF† 5,600 allowing for MS/MSALL high-
resolution and high mass accuracy analysis as previously
described (37). Lipids were quantified using an in-house
library on MultiQuantTM software.
High-resolution proteomic and lipidomic analysis of EVs
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Analysis
EVs were purified from source cells on 6 independent
days, and 3 replicate samples of cells, MVs and exosomes
of each source cell type were used for proteomics analysis
and the second set of 3 biological replicates of each
sample type for lipidomics analysis. Lipidomic analysis
additionally included 2 technical replicates of each bio-
logical replicate. Label-free quantification of proteins was
performed via the iBAQ [intensity-based absolute quan-
tification (38)] method in Scaffold Viewer (Proteome
Software). Briefly, precursor ion intensities of peptides
matching to each particular protein were divided by the
theoretical number of peptides that could be derived from
each particular protein by trypsin digestion. Lipidomic
quantitation of molecular species and lipid classes were
normalized to the protein content of samples.
Since we collected a large data set without any a priori
hypothesis, statistical analysis involved several hypothesis-
generating methods. First, we compared total protein
profiles (individual iBAQ values) and lipid profiles (nmol
of lipid species normalized to total protein content) of
exosomes, MVs and source cells by pairwise Pearson’s
correlation in Microsoft Excel and used R2 to characterize
the level of similarity between samples. Another statistical
method to explore big data derived from several sample
types is principal component analysis (PCA). We normal-
ized protein (individual iBAQ values) and lipid (nmol
of lipid species normalized to total protein content)
profiles of exosomes and MVs to the protein and lipid
profile of their source cells and ran PCA in R (‘‘prcomp’’
command). We also visualized the normalized protein
and lipid profiles of exosomes and MVs on heatmaps,
which we generated by the ‘‘pheatmap’’ and ‘‘heatmap3’’
packages in R. We also used gene ontology (GO) analysis
to annotate biological function to proteins enriched in
EVs [DAVID version 6.7 (39,40), NIH].
Results
We sought to characterize the protein and lipid composi-
tion of exosomes and MVs and to determine whether the
protein and lipid content depends on source cell type.
Although it does not provide full separation of MVs and
exosomes, differential ultracentrifugation is currently the
gold standard method of EV purification (14). Hence, for
the purposes of this publication, we will refer to the
10,000g pellet as MVs, and to the 100,000g pellet as
exosomes (Fig. 1). We purified exosomes and MVs from
the conditioned cell media of U87, Huh7 and MSC
(Fig. 1). As expected, exosomes were relatively homoge-
neous with an average diameter of approximately 135 nm
(50200 nm; Fig. 2a). MVs, however, were more hetero-
geneous in size (50600 nm). We then analysed the protein
content of EVs and source cells by liquid chromatography
followed by tandem mass spectrometry (LCMS/MS)
and the lipid content using an information-independent
acquisition method known as MS/MSALL (37). Protein
and lipid contents of EVs from each cell type were
compared with the total protein and lipid contents of the
respective source cell type in downstream analyses (Fig. 1).
Exosomes differ from microvesicles in protein
composition
To assure that we purified bona fide EVs, we confirmed
membrane-surrounded vesicular structures in all the EV
isolates on EM (Supplementary Fig. 1a) and investigated
the presence of known exosomal marker proteins and
absence of non-vesicular proteins in our EV preparations.
As expected, nuclear and Golgi-resident proteins were
few or absent from MVs and exosomes (Fig. 2b), while the
ER marker calnexin was absent from exosomes but present
in MVs (Supplementary Fig. 1b). Enrichment of EV
marker proteins showed significant source cell type
dependence. Traditional exosome markers CD81 and
CD9 (41) were enriched in both exosomes and MVs, with
level of enrichment being higher in exosomes (Fig. 2c and
Supplementary Fig. 1b). CD63 enrichment was specific to
U87 and Huh7 exosomes, while Tsg101, PDCD6IP (Alix)
and CD82 were only enriched in U87 exosomes (Fig. 2c
and Supplementary Fig. 1b). Flotillin-1 and tetraspanin-4
were highly enriched in all U87 and Huh7 EVs, while PLP2
enrichment was unique to MSC MVs (Fig. 2c). The
immunoblot of individual protein markers corresponded
well with label-free quantification of proteomics. Gener-
ally, 91% of top EV marker proteins [n100; ExoCarta
(42)] were present in our EV samples (Supplementary
Table I).
Pairwise Pearson’s correlation of protein levels (iBAQ
scores) revealed that exosomes were more different from
source cells (R2B0.1) than MVs were (R20.280.66).
Exosomes also differed from MVs (R2B0.2) (Fig. 3a).
Hence, exosomes and MVs displayed a very different protein
profile, despite overlap in their size range (Fig. 2a).
Exosomal proteomes effectively distinguish between
cancer origin and MSC origin
Huh7 and U87 exosomes had similar protein composi-
tions (R20.8), despite poor correlations between MV
(R20.23) and source cell (R20.37) protein levels (Fig.
3b). These data suggested that exosomal proteome was
similar between source cell types, whereas MV proteome
differed between source cell types. However, MSC exo-
somes markedly differed from U87 and Huh7 exosomes
(R20.035 and 0.004). Furthermore, this contrast could
not be explained by the difference in source cell protein
compositions (MSC to U87, R20.57 and MSC to Huh7,
R20.28). To look at cell type-specific protein enrichment
in EVs, we normalized EV protein levels (iBAQ scores) to
their respective source cell type’s protein levels. Then,
we used PCA to determine whether source cell type
affected, which proteins were enriched in EVs. Indeed,
Reka A. Haraszti et al.
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MSC-derived exosomes and MVs clustered very close
together and clearly segregated from U87 and Huh7
vesicles (Fig. 3c).
Over-represented protein pathways depend on
vesicle type
To compare functional content of exosomes and MVs, we
conducted GO analysis on the list of 719 proteins present
in exosomes from all 3 cell types and the 1,357 proteins
present in MVs from all 3 cell types using DAVID version
6.7 (39,40) (NIH) (Fig. 4a). GO is a knowledgebase,
where genes are assigned to molecular functions, cellular
components or biological processes (GO terms). GO
analysis tests whether the representation of GO terms in a
specific set of genes could be explained by random
chance or does it enrich for certain GO terms. We found
that exosomes and MVs were both enriched in vesicle
proteins, membrane-associated proteins and GTPases
(20) (Fig. 4b). Both exosomes and MVs were also
enriched for translation and glycolysis pathways.
Meanwhile, certain GO termswere differentially enriched
in exosomes and MVs. Extracellular matrix, receptors,
heparin-binding, phospholipid-binding, integrin, immune
response and cell adhesion functions were characteristic for
exosomes, whereas mitochondrial, endoplasmic reticulum
and proteasomal functions were exclusive to MVs (Fig. 4b).
To examine how cell type influences protein enrichment
in EVs, we normalized EV protein content (iBAQ values)
to the respective source cell protein content and performed
unsupervised cluster analysis, which revealed 9 clusters
described in Fig. 5 and Supplementary Table II.
Clusters 1, 7 and 8
Proteins in clusters 1,7 and 8 were depleted from vesicles of
U87 cells, Huh7 cells, or both, and absent in all MSC samples.
These clusters comprised nuclear proteins, consistent with
Fig. 1. Workflow of EV preparation and mass spectrometry. Mesenchymal stem cells (MSCs), glioblastoma cells (U87)
and hepatocellular carcinoma cells (Huh7) were cultured, and EVs prepared on 6 different days by differential ultracentrifugation.
Resulting samples (cells, microvesicles and exosomes, altogether 54 samples) were subjected to proteomic (27 samples, LCMS/MS)
and lipidomic (27 samples, MS/MSALL) analyses. Proteins were quantified by the label-free quantification method iBAQ (intensity-based
absolute quantification, see details in materials and methods section). Analysis detected 3,531 proteins and 1,961 lipid species (defined by
head group identity, length, saturation and number of fatty acid tails) in 22 lipid classes (defined by head group identity). Level of proteins
and lipids in exosomes and microvesicles were later normalized to their respective source cells and expressed on a log(2) scale.
High-resolution proteomic and lipidomic analysis of EVs
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quality control experiments showing the depletion of nuclear
proteins (Fig. 2b).
Cluster 2
Proteins in cluster 2 were depleted from exosomes but
not from MVs. This cluster consisted of proteins that
function in mitochondria or endoplasmic reticulum,
consistent with the MV-specific GO terms we identified
in Fig. 4 and with an analysis of the relative abundance of
endoplasmic reticulum and mitochondrial marker pro-
teins (Supplementary Fig. 2).
Clusters 3 and 9
Proteins in clusters 3 and 9 were enriched or unchanged in
EVs regardless of cell type or vesicle type. These clusters
consisted of membrane proteins, vesicular proteins, extra-
cellular matrix, heparin-binding, cell adhesion pathways.
Furthermore, GO analysis detected enrichment in certain
protein motifs (e.g. epidermal growth factor (EGF)-like
domain) and post-translational modifications (e.g. disul-
phide bonds and glycosylation), consistent with the enrich-
ment of membrane proteins. We did not observe an
enrichment of proteins known to be palmitoylated, a
posttranscriptional modification that has been shown to
direct protein accumulation in exosomes (43).
Clusters 5 and 6
Proteins in clusters 5 and 6 were enriched in vesicles of
Huh7 (cluster 5) or U87 (cluster 6) cells. Huh7-specific
cluster 5 consisted of proteins involved in exocytosis,
Fig. 2. Quality control of EV preparations. (a) Representative size distribution profiles of EVs from 3 different cell sources as obtained
by Nanoparticle Tracking Analysis (NanoSight NS300, Malvern). Microvesicles were more heterogeneous in size independently of cell
source. (b) EVs are depleted in proteins of nuclear or Golgi origin. Origin of proteins was identified by Scaffold Proteome Software. (c)
Enrichment of exosomal marker proteins in EVs. Fold change of proteins in EVs versus source cells is colour-coded on a log(2) scale.
Enrichment of established protein markers in exosomes was source-cell-type-dependent and most exosomal markers were, although to a
lower extent, also enriched in microvesicles.
Reka A. Haraszti et al.
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whereas U87-specific cluster 6 included endocytosis path-
way proteins. These observations show source cell-dependent
EV content, which may suggest source cell-dependent
exosome production and maturation mechanisms. When
focusing on 2 protein classes, vesicular trafficking regu-
lator Rabs (Supplementary Fig. 3) and EV organotropism
Fig. 3. Protein and lipid sorting into EVs are not linked. Pairwise Pearson’s correlations of protein and lipid levels in cells, microvesicles
and exosomes derived form 3 source cell types. Numbers represent R2. (a) Microvesicular proteome was more similar to the source cell
than the exosomal proteome was in all 3 cell types investigated. (b) Cancer cell-derived proteomes (U87 and Huh7) were increasingly
similar to each other and increasingly different from stem cell proteome (MSC) while moving from cells towards microvesicles and
exosomes. (c) Principal component analysis of protein levels in exosomes (round) and microvesicles (square) normalized to their
respective source cell. MSC-derived exosomes and microvesicles segregate from cancer cell EVs. (d) Lipidomes of exosomes,
microvesicles and source cells are more similar to each other than their proteomes are. (e) Huh7 and MSC lipidomes showed increasing
levels of similarity moving from source cells to microvesicles to exosomes. (f) Principal component analysis of lipid levels in exosomes
(round) and microvesicles (square) normalized to their respective source cell. MSC- and Huh7-derived EVs increasingly cluster together
and segregate from U87 moving from microvesicles to exosomes.
High-resolution proteomic and lipidomic analysis of EVs
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regulator integrins (44) (Supplementary Fig. 4), source cell
influence on EV content was particularly clear. Endocy-
totic Rab34 and Rab23 were highly enriched in U87
exosomes, retrograde transport Rab9 and Rab6 were
enriched in Huh7 exosomes, and exocytotic Rab27 was
enriched in MSC exosomes (Supplementary Fig. 3). While
integrin b3 was enriched in all EVs except Huh7 MVs,
integrins a2b [indicated in lung-tropism (44)] and a6 were
specific to MSC EVs, integrins a1, a2 and a5 were cha-
racteristic to Huh7 EVs, and integrins a3, a7, aV [liver-
tropic (44)], b1 [lung-tropic (44)] and b5 [liver-tropic (44)]
were characteristic to U87 EVs (Supplementary Fig. 4).
Lipid and protein enrichment in EVs are not linked
MS/MSALL analysis identified 22 lipid classes (defined by
head group) and almost 2,000 lipid species (defined by
head group, fatty acid tail length and saturation) across all
samples. Lipid content was more similar between samples
(R20.410.93) than was protein content (R20.004
0.66) (Fig. 3d and e). Surprisingly, lipid enrichment in EVs
did not follow the pattern of protein enrichment we
observed earlier (Fig. 3ac): lipid content of U87 and
Huh7 exosomes was different (R20.47), despite their
protein content being very similar (R20.8) (Fig. 3b and
e). Instead, lipid composition of Huh7 and MSC exo-
somes showed striking similarity (R20.93). This simi-
larity was present, although less pronounced, between
Huh7 and MSC MVs as well (R20.73; Fig. 3e). Again,
similarity in lipid profiles did not correlate with difference
in protein profiles of Huh7 and MSC exosomes
(R20.004), or MVs (R20.13) (Fig. 3b). High degree
of similarity between Huh7 and MSC exosomes could not
be explained by source cell lipid profiles either (Fig. 3e;
R20.5). When lipid levels in EVs were normalized to
their respective source cells and underwent PCA, Huh7
and MSC exosomes clustered very close to each other and
segregated from U87 vesicles (Fig. 3f). Huh7 and MSC
MVs showed a less clear segregation from U87 EVs.
Taken together, certain source cells differing in protein
and lipid composition enriched the same proteins but not
the same lipids (U87 and Huh7), and yet other source cells
enriched the same lipids but not the same proteins (Huh7
and MSC) in their EVs. These data suggested that protein
and lipid enrichment mechanisms were not linked.
Fig. 4. Over-represented protein pathways depend on vesicle type. (a) Venn diagrams of detected proteins in exosomes and microvesicles
of 3 different source cell types. MSC EVs had a lower diversity of proteins. (b) Proteins shared among exosomes or microvesicles derived
from all 3 source cell types (middle section in the Venn diagrams) underwent gene ontology analysis. The negative logarithm of p-values
is shown for each GO term, colourful lines represent significance threshold (p0.05). Common (depicted in black), as well as distinct
(depicted in colour) pathways emerged in exosomes versus microvesicles.
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Next we asked, whether Huh7 and MSC shared
characteristics that could possibly relate to their similar
exosomal lipid composition. We observed that Huh7 and
MSC yielded significantly fewer and smaller exosomes
(73 /cell and 36 /cell, 129914 and 131912 nm, respec-
tively) than U87 cells (1,382 /cell, 14898 nm).
Lipid enrichment in EVs correlates with head group
charge, tail length and saturation
The concentration of the 1,961 detected lipid species
(defined by head group, number, length and saturation of
fatty acid tails) in EVs was normalized to respective
source cell lipidome. Colour coding of enrichment (red)
and depletion (blue) of lipids (Fig. 6 and Supplementary
Table III) in EVs versus source cells showed a
good concordance between triplicate measurements and
confirmed that MSC and Huh7 exosomes displayed a
very similar lipid composition. Next, we were interested
whether enrichment or depletion in EVs versus source
cells depended on head group or fatty acid tail char-
acteristics. Hence, we created a sidebar on the left,
which colour-coded 3 characteristics of each lipid species:
charge of its head group [negative (green), neutral (navy)
or zwitterionic (magenta)], average length (the darker,
the longer) and average saturation (the darker, the more
double bonds) of its fatty acid tails. The colours and grey
shades partially followed unsupervised clustering of
lipids indicating that head group charge as well as tail
length and saturation correlated lipid enrichment in
EVs. Specifically, MSC MVs (p0.007), U87 exosomes
(p0.004) and U87 MVs (p0.006) were enriched in
zwitterionic lipid head groups (phosphatidylcholines
and/or phosphatidylethanolamines) and depleted in other
head groups. MSC exosomes, MSC MVs and Huh7
exosomes were enriched in long lipid species (more than 60
carbons, p50.001, p0.041 and p50.001, respectively)
and polyunsaturated lipid species (more than 10 double
bonds, p0.006, 0.038 and 0.001, respectively).
Lipid class enrichment in EVs depends on vesicle
type and source cell type
The 22 lipid classes detected could be sorted into groups
marking enrichment in MVs or exosomes, depletion in most
EVs or no change in EVs relative to source cells (Fig. 7).
Ceramides and sphingomyelins were consistently en-
riched in all MVs, whereas cholesterol esters showed
enrichment only in MSC and Huh7 MVs and acyl carni-
tines and lysophosphatidylcholines only in MSC MVs
(Fig. 7, upper panel). These lipid classes were depleted
from or unchanged in exosomes, with the exception of
marked sphingomyelin enrichment in U87 exosomes.
Glycolipid, free fatty acid and phosphatidylserine enrich-
ment characterized all exosomes and were depleted from or
unchanged in MVs, except for phosphatidylserine enrich-
Fig. 5. Heatmap of all protein levels in EVs normalized to their respective source cells. iBAQ values of proteins in EVs were normalized
to the corresponding protein levels in source cells, expressed on a log(2) scale and colour-coded. Depletion is depicted in blue and
enrichment in red. Clusters from heatmap underwent gene ontology analysis, and terms significantly enriched are shown on the right.
TM, transmembrane; ECM, extracellular matrix; ER, endoplasmic reticulum; CAM, cell adhesion molecule; VLDL, very low density
lipoprotein; diS, disulphide.
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ment in U87 MVs (Fig. 7, upper middle panel). The free fatty
acids most enriched in MSC and Huh7 exosomes were fully
saturated (data not shown). Cardiolipins were markedly
enriched in MSC and Huh7 exosomes only. Lyso derivatives
(where 1 fatty acid tail is removed by hydrolysis) of phospha-
tidylserines, phosphatidylglycerols and phosphatidylinositols
showed enrichment in MSC and Huh7 exosomes, whereas
lyso-phosphatidylethanolamines were rather enriched in
U87 exosomes. These lysoderivatives were also enriched
in MSC MVs but depleted from U87 and Huh7 MVs.
Structural membrane lipids, including phosphatidylgly-
cerols, phosphatidylinositols and phosphatidylethanola-
mines, showed depletion from all exosomes and most MVs
(Fig. 7, lower middle panel). Phosphatidylcholines were
depleted in exosomes but unchanged or enriched in MVs.
Depletion in diacyl and triacylglycerols in EVs was most
pronounced in Huh7 cells, which had a high baseline level
of these lipid classes.
The concentration of phosphatidic acids and their
lysophosphatidyl derivatives did not differ between
source cells and EVs (Fig. 7, lower panel).
Taken together, both vesicle type and source cell type
affected the lipid composition of EVs.
Discussion
EVs consist of heterogeneous subgroups, which are
difficult to fully distinguish by current purification meth-
ods. Here, we showed that (a) exosomes and MVs could
Fig. 6. Lipid enrichment in EVs correlates with head group charge and fatty acid tail length and saturation. Lipid species levels in EVs
were normalized to the corresponding lipid levels in source cells, expressed on a log(2) scale and colour-coded. Depletion is depicted in
blue and enrichment in red. Sidebar on the left encodes 3 characteristics of a lipid species: headgroup charge (in colour), average length
of fatty acid tails (greyscale) and average level of saturation of fatty acid tails (greyscale). Lipid species clustered not only according to
head group charge but also according to length and saturation of tails.
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Fig. 7. Lipid class enrichment in EVs depends on vesicle type and source cell type. Percentage of each lipid class within a sample is
depicted on slope charts and lipid class grouped according to their enrichment in microvesicles (upper panel), enrichment in exosomes
(upper middle panel), depletion in most EVs (lower middle panel) or no difference between EVs and source cells (lower panel). Source
cells are depicted in black, exosomes in red and microvesicles in blue. Since different lipid classes represent vastly different percentage of
cells’ or vesicles’ lipid composition, the scale of the y-axes shows a corresponding variability.
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be well distinguished on the proteome level but did not
display source cell-independent, vesicle type-specific
protein markers, (b) proteome but not lipidome of EVs
distinguished cancerous source cells from stem source
cells, (c) protein and lipid enrichment in EVs compared
to source cells were not linked. Furthermore, the current
study provides the largest data set of EV lipid content
to date.
We observed cell-type-specific enrichment of proteins
and lipids in EVs. The clear difference between composi-
tion of source cells and EVs indicated that lipids and
proteins are likely actively sorted into EVs. However, the
enrichment of commonly used exosome markers was
source-cell-type dependent, and although to a different
extent, all exosomal markers were enriched in MVs as
well. Enrichment of Rab proteins in EVs, a protein family
indicated in exosomal biogenesis (45), showed marked
source cell dependency, suggesting that protein sorting
mechanisms into EVs may depend on source cell type.
Commonly enriched pathways in EVs correlated well with
previously described behaviours of EVs [such as heparin-
binding (46), immune response stimulation (32,47), in-
tegrin content (44) and antiphagocytic CD47 (48) of
exosomes and mitochondrial, proteasomal and ER con-
tent of MVs (16,49)]. GO analysis found enrichment of
certain post-translational modification motifs (e.g. glyco-
sylation and prenylation) common to all EVs, although
the exosome targeting palmitoyl modification (43) was
not detected. We were not able to detect any protein
biomarkers that were enriched in exosomes of all source
cells and at the same time depleted in MVs of all source
cells. Nevertheless, we showed that exosomal and MV
content on the proteome level differed significantly
from each other independent of source cell type. There-
fore, we suggest that the correlation between exosome
and MV content could be explored as an additional
biomarker for ‘‘vesiculome’’ (mass spectrometry and
RNASeq) studies.
Protein enrichment in exosomes distinguished cancer
cells from the stem cells used in this study. If further studies
on EVs derived from multiple malignant and benign cell
types will confirm this observation, then protein enrich-
ment in exosomes might become a particularly useful
general cancer marker. Furthermore, this phenomenon
suggests that stem cells and cancer cells may use different
mechanisms to sort proteins into EVs. Hence, the biomarker
value of exosomes might lie in indicating sorting dysregu-
lation in their source cells, whereas MVs are valuable for
reflecting the content of their source cells.
Protein and lipid sorting into EVs did not appear to be
linked: U87 and Huh7 (cancerous) cells enriched similar
proteins but different lipids in their EVs, while Huh7 and
MSC (yielding few and smaller exosomes) cells enriched
similar lipids but different proteins in their EVs. Hence,
protein sorting into EVs associated best with stem or
cancer cell origin in this study, whereas lipid sorting
associated best with yield and size of exosomes. Further
studies are needed to confirm whether these associations
explain EV biogenesis mechanisms.
The current study mapped EV lipidome to a great depth,
identifying almost 2,000 lipid species. Since lipids are not
coded in the genetic code and biological functions of most
lipids detectable by mass spectrometry are unknown, data
interpretation may follow biochemical/structural princi-
ples. Here, we showed that not only head group identity but
also head group charge, fatty acid tail length and satura-
tion contributed to lipid enrichment in EVs. These
parameters modify the head group-to-tail size ratio, which,
in turn, defines the spontaneous curvature of a lipid
monolayer. Since EVs are small vesicles, their limiting
bilayer membranes are highly curved. We found exosomes
to be enriched in positive curvature promoting (free fatty
acids and lysophosphatidyl derivatives, both having 1 tail
only and favouring outer membranes) as well as negative
curvature promoting (cardiolipins having 4 tails and
favouring inner membranes) lipids. While cardiolipin is
believed to exclusively reside in the inner mitochondrial
membrane (a highly curved membrane itself), other
mitochondrial contents (proteins) were specifically de-
pleted from the same Huh7 and MSC exosomes. These
data suggest that cardiolipin must be actively sorted into
exosomes of Huh7 cells and MSCs, and it might function
to stabilize these unusually small vesicles. However, a wider
screen of source cell types is necessary to establish a firm
correlation between cardiolipin content and exosome size.
Furthermore, it is intriguing to speculate that anti-
cardiolipin antibodies present in several autoimmune
diseases (50) might partially be generated due to the
presence of cardiolipin on circulating exosomes.
Sphingomyelins and ceramides have been implicated in
exosomal biogenesis in brain cells [oligodendrocytes (51),
neurons (52), neuroblastoma (53)] but not in in PC-3
cells (54). We found enrichment of sphingomyelins in U87
glioblastoma (a brain cell type) exosomes only, whereas
both sphingomyelins and ceramides were characteristically
enriched in all MVs. Ceramide-triggered exosome forma-
tion pathway is thought to be independent of the
endosomal sorting complexes required for transport
(ESCRT)-mediated exosome formation pathway (51) and
controls the packaging of only a subset of proteins into
exosomes (52). Hence, source cell type may influence, which
pathway is predominantly involved in exosome formation
and which lipid sorting mechanism is applied. Different
exosome formation pathways may overlap with MV forma-
tion pathways in a source-cell-type-dependent manner.
We found that structural plasma membrane lipids,
including phosphatidylcholines, phosphatidylinositols,
phosphatidylglycols and phosphatidylethanolamines, were
depleted, whereas phosphatidylserines showed a mild
enrichment in exosomes but not in MVs. These data are
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consistent with previous findings showing depletion of
phosphatidylcholines and enrichment of phosphatidylser-
ines in exosomes (28). These lipids comprise the majority
of membranes, and their levels in MVs were more similar to
source cells than their levels in exosomes.
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